Zoya Demidenko: Researcher in Cancer Biology
Zoya Demidenko is a notable researcher associated with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, establishing a robust foundation in life science research.
Her academic output spans a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cell senescence, and cancer biology. To date, she has co-authored more than 46 scientific publications, which have accumulated over 4,100 references — a indicator to the impact of her findings.
Among her most notable discoveries concerns explaining the processes of cell aging. Her research demonstrated that when the cellular division cycle is halted while cellular expansion persists, cells enter senescence. Crucially,
Zoya Demidenko established that this process is pharmacologically suppressed using agents such as rapamycin.
Zoya Demidenko has also brought substantially to oncological therapy research, particularly in the area of selective cell protection — a approach designed to protecting non-cancerous tissue from cytotoxic treatment whilst leaving malignant cells exposed. This method carries major promise for diminishing the adverse effects of oncological therapy.
Across her career, Demidenko has collaborated with leading scientists internationally, including Dr. Mikhail Blagosklonny. Her research can be found in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33,
Zoya Demidenko is recognized as a influential contributor in modern biomedical research, whose results keep to influence our comprehension of the way biological cells grow old, interact with therapy, and the ways in which malignant disease can be better targeted.
https://www.sciencedirect.com/science/article/abs/pii/037811199400784P
